NewTimeSpace News: Shanghai Henlius Biotech, Inc. (02696.HK) announced that the first patient has been dosed in the Phase I clinical research of self-developed injectable HLX316, a B7-H3-targeting sialidase Fc fusion protein, for advanced and metastatic solid tumors in China. As an innovative first-in-class B7-H3-targeting sialidase heterodimer, no equivalent product has obtained marketing approval globally.
Recently, enterprises related to large language models have entered a period of intensive product releases. A multi-polar, multi-functional application landscape is unfolding across the board.Catalyzed by industry and company news, stocks related to the large model concept have performed well this week. As of the market close on May 22, Zhipu saw a weekly gain of over 20%, Mininglamp Technology-W rose over 10% for the week, and stocks such as MINIMAX and Xunce experienced significant rebounds on May 22.
NewTimeSpace News: Hangzhou Diagens Biotechnology Co., Ltd. (02526.HK) announced that its core product AI AutoVision® was granted the Class III Medical Device Registration Certificate by the National Medical Products Administration (NMPA) on May 20, 2026. The approved indications cover chromosome karyotype analysis for prenatal diagnosis of birth defects using amniotic fluid samples, and chromosome karyotype analysis for assisted reproductive technology using peripheral blood samples. This is the world's first Class III medical device registration certificate for chromosome karyotype analysis with anomaly recognition capability at Level 3 (L3) autonomy, and also the first medical device registration certificate based on large model technology.
NewTimeSpace (newtimespace.com) News:On May 22, 2026, Zhipu (02513.HK)experienced a significant intraday rally. As of 13:12, the stock was trading at HK$1,245, an increase of 23.27%, setting a new all-time high for the company's share price.
NewTimeSpace News: MOG DIGITECH (01942.HK) plans to conduct a rights issue on the basis of \\"2 for 1\\", with estimated net proceeds of HKD 43.2 million.
NewTimeSpace News: May 21, 2026, VTECH HOLDINGS(00303.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at USD 2.03 billion, decreased by 6.88% YoY
NewTimeSpace News: May 21, 2026, TONGCHENGTRAVEL(00780.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at CNY 5.01 billion, increased by 14.35% YoY
NewTimeSpace News: May 21, 2026, NTES-S(09999.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at CNY 30.59 billion, increased by 6.11% YoY
NewTimeSpace News: May 21, 2026, BOYAA(00434.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at HKD 133.29 million, increased by 19.12% YoY
NewTimeSpace News: May 21, 2026, NIO-SW(09866.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at CNY 25.53 billion, increased by 112.16% YoY
NewTimeSpace News: May 21, 2026, SHING CHI HLDGS(01741.HK) released its Interim Report for the period ended September 30, 2026, Total Revenue stood at HKD 76.69 million, decreased by 10.35% YoY
NewTimeSpace News: May 22, 2026, LENOVO GROUP(00992.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at USD 83.07 billion, increased by 20.26% YoY
HUTCHMED (00013.HK) will present Phase II registration study data for savolitinib in MET-amplified gastric cancer or gastroesophageal junction adenocarcinoma (GEA) at the 2026 ASCO Annual Meeting, demonstrating an IRC-assessed ORR of 32.3%, a DCR of 63.1%, and a median PFS of 4.0 months. The relevant NDA was accepted and granted Priority Review in December 2025. Further analysis results from multiple studies of fruquintinib and surufatinib will also be released.
KELUN-B (06990.HK) will announce Phase 3 data for sac-TMT combined with pembrolizumab as a first-line treatment for PD-L1-positive advanced NSCLC (median PFS: NR vs. 5.7 months, $HR = 0.35$) and Phase 2 data for lemborertinib fumarate in RET fusion-positive NSCLC (ORR of 87.1% in pretreated patients) at the 2026 ASCO Annual Meeting. Both registration studies have been selected for oral presentations, and relevant marketing applications have been accepted by the NMPA.
LEGEND HOLD (03396.HK) subsidiary Lenovo Group announced its full-year results for FY2025/26 ended March 31, 2026. Revenue rose 20.3% year-on-year to USD 83.075 billion. Profit attributable to equity holders of the company reached USD 1.912 billion, up 38.2% year-on-year, with basic earnings per share at 15.63 US cents.
NewTimeSpace News: MoneyMax announced on May 21 that its wholly-owned subsidiary MoneyMax Treasure has issued S$30 million 5.00% fixed rate notes. These notes will be consolidated with its previously issued S$100 million similar notes into one series, and are expected to be listed on the Singapore Exchange on May 22, 2026.
